市場調查報告書
商品編碼
1371982
全球腦圖設備市場,到 2030 年的預測:按產品類型、最終用戶和地區分類的全球分析Brain Mapping Instruments Market Forecasts to 2030 - Global Analysis By Product Type, End User and By Geography |
根據Stratistics MRC預測,2023年全球腦圖設備市場規模將達25億美元,預計2030年將達到42億美元,預測期內年複合成長率為8.1%。
腦圖譜是切除腫瘤時檢測和保護關鍵大腦區域最準確的技術。對於腫瘤靠近大腦言語、運動或感覺部分的患者來說,這種手術可能是必要的。醫生可以盡可能切除腦腫瘤,同時盡量減少對控制運動、語言和感覺的大腦重要區域的影響。
根據世界衛生組織(WHO)2021年9月的最新資訊,2021年全球約有5500萬人患有失智症,每年報告的病例近1000萬例。
目標人口中神經系統疾病的流行意味著腦圖設備在醫療設備業的使用可能會更加迅速地擴大,為這些工具的市場創造了新的機會。此外,技術進步預計將導致全球幾家領先公司推出更多新產品,預計將對市場成長產生積極影響。
購買和維護腦圖設備(例如 MRI 掃描儀、腦電圖系統和腦磁圖機)的成本可能很高。這些設備的高成本可能是一個限制,特別是對於資金有限的醫療機構。設備成本可能會阻礙普及,特別是在資源有限的地區。
隨著腦部影像和圖譜技術的不斷發展,腦圖譜設備市場潛力巨大。為了更準確地繪製大腦活動圖,功能性磁振造影(fMRI)、腦電圖 (EEG) 和腦磁圖 (MEG) 等新影像技術可提供更高的空間和時間解析度。此外,技術的發展導致繪製人腦圖的設備變得更加複雜和精確。這些技術提供了更強大的資料收集和分析能力、更高品質的影像以及改進的與其他系統和設備的通訊。這些進步使科學家和研究人員能夠更好地了解大腦如何運作、神經網路如何運作以及相關疾病如何運作。
並非所有地方都能平等獲得腦圖設備,尤其是在農村和低收入國家。缺乏基礎設施,包括醫療設施和合格的工人,可能會限制腦圖設備的取得和使用。然而,有限的存取限制阻礙了這些技術的普遍普及,從而限制了市場的擴張。
COVID-19 是一場意想不到的全球公共衛生緊急事件,幾乎影響著所有企業。例如,根據 2021 年 12 月發表在《阿茲海默症期刊》上的一篇論文,COVID-19 不僅影響呼吸系統,還會引起神經和神經精神疾病。報告稱,該病毒會影響中樞神經系統(CNS),即使在 COVID-19 症狀消退後也可能導致認知障礙。結果,COVID-19 感染者的神經症狀惡化。於是就需要腦圖設備,這對疫情期間的市場拓展產生了重大影響。
由於住院患者數量的增加和主要市場參與企業推出的產品,醫院部門在預測期內佔據最大佔有率。此外,美國醫院數量的增加正在刺激市場擴張。根據美國心臟協會(AHA)2021年1月發布的數據,2021年美國投資者擁有的(營利性)社區醫院數量為1,228家,而州和地方地方政府醫院的數量為951家。此外,大量醫院產生對腦圖設備的需求,預計將推動市場擴張。
由於能夠使用影像技術診斷癲癇和癲癇等腦部疾病,腦電圖 (EEG) 領域預計在預測期內具有最高的年複合成長率。此外,腦電圖是一種有助於識別大腦電活動變化的診斷方法。因此,檢測各種大腦挑戰的快速應用進程正在推動市場擴張。
由於美國神經系統疾病罹患率不斷上升、新技術接受度較早以及醫療基礎設施不斷加強,北美目前在全球腦圖設備市場佔據主導地位。例如,據阿茲海默症協會稱,2021年約有620萬65歲以上的美國將患有阿茲海默失智症,預計到2050年這一數字將上升至1,270萬。此外,高度發展的醫療保健系統和對研發的重視為該地區最尖端科技的實施提供了有利的環境。這些因素正在推動該地區的成長。
由於健康問題日益嚴重和最尖端科技的日益採用,預計亞太地區將在預測期內快速擴張。 NCBI 報告稱,該地區神經系統疾病的患病正在增加,導致大腦結構和認知功能的影像研究增加。此外,平面回波成像 (EPI) 等新方法正在用於治療腦部疾病患者。快速磁振造影技術(EPI)可以在很短的時間內取得磁振造影影像。因此,腦部疾病的流行和該地區最尖端科技的採用正在推動市場擴張。
According to Stratistics MRC, the Global Brain Mapping Instruments Market is accounted for $2.5 billion in 2023 and is expected to reach $4.2 billion by 2030 growing at a CAGR of 8.1% during the forecast period. The most accurate technique to detect and safeguard important brain regions while removing a tumor is through brain mapping. This operation may be necessary for patients whose tumors are close to the linguistic, motor, or sensory parts of the brain. Doctors have been able to remove as much of a brain tumor as feasible while limiting the effect on the vital regions of the brain that regulate movement, speech, and the senses.
According to the September 2021 update by the World Health Organization (WHO), about 55 million people worldwide were living with dementia in 2021, and nearly 10 million cases are reported every year.
The prevalence of neurological disorders among the target population means that the use of brain mapping instruments in the medical device industry is likely to grow more rapidly, opening up new opportunities for the market for these tools. Additionally, the increased introduction of new products by several major players globally as a result of enhanced technology is anticipated to positively affect market growth.
The cost of purchasing and maintaining brain mapping equipment like MRI scanners, EEG systems, and MEG devices can be high. These instruments' high costs can be a constraint, especially for healthcare facilities with limited funds. The cost of the tools may prevent their widespread use, particularly in areas with limited resources.
The market for brain mapping instruments has a lot of potential due to the ongoing developments in brain imaging and mapping technology. In order to map brain activity more precisely, new imaging techniques, including functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and magnetoencephalography (MEG), offer greater spatial and temporal resolution. Additionally, technology development has produced more complex and precise instruments for mapping the human brain. These technologies provide better data collection and analysis capacities, higher-quality images, and improved communication with other systems and devices. These advancements offer scientists and researchers a better understanding of how the brain works, how neural networks work, and how related illnesses work.
Not all locations have equal access to brain mapping instruments, particularly rural and low-income nations. The accessibility and availability of brain mapping tools may be constrained by a lack of infrastructure, including healthcare facilities and competent workers. However, as it prevents the general adoption of these technologies, this restricted accessibility limits market expansion.
An unexpected global public health emergency, COVID-19, has had an impact on practically every business. For instance, COVID-19 not only affects the respiratory system but also causes neurological and neuropsychiatric diseases, according to an article published in the Journal of Alzheimer's Diseases in December 2021. According to this, the virus may have an impact on the central nervous system (CNS), which could lead to cognitive impairment even after COVID-19 symptoms have subsided. As a result, people with COVID-19 developed worse neurological conditions. As a result, there was a need for brain mapping instruments, which had a major effect on market expansion during the epidemic.
Due to a rise in hospital admissions and product launches by the major market participants, the hospital segment dominated the largest share over the forecast period. The expansion of the market is also being fueled by the rising number of hospitals in the United States. According to numbers from the American Heart Association (AHA) released in January 2021, there were 1,228 investor-owned (for-profit) community hospitals in the United States in 2021, compared to 951 state and local government community hospitals. Moreover, the demand for brain mapping instruments is generated by the enormous number of hospitals, which is anticipated to fuel market expansion.
Due to its capabilities of using imaging techniques to diagnose brain illnesses, including epilepsy and seizures, the electroencephalography (EEG) segment is anticipated to have the highest CAGR throughout the projection period. Moreover, it is a method of diagnosis that aids in identifying alterations in the electrical activity of the brain. Therefore, it is promoting market expansion due to its quicker application process for detecting various brain challenges.
Due to the rising incidence of neurological illnesses, early acceptance of new technologies, and enhanced healthcare infrastructure in the US, North America currently holds a dominant position in the global market for brain mapping instruments. For instance, according to the Alzheimer's Association, in 2021, there were around 6.2 million Americans 65 and older who had Alzheimer's dementia, and that number is predicted to rise to 12.7 million by the year 2050. Moreover, the highly developed healthcare system and concentration on research and development provide a climate that is favorable to the adoption of cutting-edge technologies in the region. These elements are boosting the region's growth.
Owing to growing health concerns and increased adoption of cutting-edge technologies, Asia-Pacific is anticipated to expand at a rapid pace over the course of the projected period. The NCBI reports that the rising prevalence of neurological illnesses in the area has led to an increase in neuroimaging investigations of brain structure and cognitive functioning. The treatment of individuals with brain illnesses has also adapted new methods, such as echo-planar imaging (EPI). The rapid MRI technique known as EPI can acquire MR images in a very short amount of time. As a result, the prevalence of brain illnesses and the adoption of cutting-edge technologies in the region have fueled market expansion.
Some of the key players in Brain Mapping Instruments market include: Advanced Brain Monitoring, Inc, Artinis Medical Systems, Canon Medical Systems Corp, General Electric Company, Gowerlabs Ltd, Koninklijke Philips N.V., Medtronic, Natus Medical Incorporated, Nihon Kohden Corporation, NIRx Medical Technologies, LLC, Siemens Healthcare Private Limited and Soterix Medical Inc.
In September 2022, Scientists at the Allen Institute established the Brain Genome Project, a new global partnership to map approximately 200 billion cells in the human brain by type and function.
In March 2022, Kernel, a neurotechnology company, developed a wearable headset device, Kernel Flow, for brain measurement, which is based on time-domain functional near-infrared spectroscopy (TD-fNIRS). The device enables accurate, high-resolution measurement of the brain, and it functions by emitting picosecond pulses of light into tissue and measuring the arrival times of single photons.